AMDL Launches Expanded Distribution With 2nd Round of Agreements Valued at $7.12 Million Annually for New Health & Beauty Produc
October 30 2007 - 8:43AM
PR Newswire (US)
TUSTIN, Calif., Oct. 30 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), with operations in Shenzhen, Jiangxi and Jilin, China,
which through its wholly owned subsidiary Jade Pharmaceutical Inc.
(JPI), is an international biopharma company that engages in the
development, manufacture and marketing of proprietary
pharmaceutical and diagnostic products, announced today that its
JPI's subsidiary JJB has signed a key set of regional distribution
agreements for its new anti-aging and skin care injectable product
under the brand name "Goodnak." This initial product is the first
in a new line of anti- aging & skin care products currently
under development by JJB. JJB has signed three new Southern Region
exclusive, one-year renewable Distribution and Agency Agreements
that were signed with Changsha Hongli Co., Ltd. ("CHC"), Wenzhou
Limeikang Trade., Ltd. ("WLT") and Xiamen Larry Beauty Technology
Co., Ltd. ("XLB"). These agreements cover the key cities in Hunnan,
Zhejiang and Fujian Provinces that have a combined population of
approximately 134.4 million people. These two separate agreements
in combination, require these new distributors to purchase a
minimum of US$7,126,496 of JJB's new Goodnak product during the
one-year period of the contracts and a minimum initial order of
US$3,563,248. Frank Zheng, managing director of JPI, said these
additional distribution agreement puts the Company on the path to
building sales of Goodnak by as much as $24 million over the next
12 months. These agreements, couple with the previously announced
agreements, provide JJB with a current total of approximately
$10.47 million in anticipated orders for its new Goodnak product.
Gary Dreher, CEO of AMDL said the Company expects to further update
the market on our expansion plans in the coming weeks. About
Goodnak: Goodnak is a high quality injectable anti-aging & skin
care product that contains an amalgam of various therapeutic
elements including human placental histosolution ("HPH"). JPI began
selling Goodnak, in August, through wholesale distribution channels
that service high-end beauty salon and plastic surgery hospitals
and medical cosmetology institutions. Goodnak product information
is available on Jade Pharma's product specific website:
http://www.jade-amdl.com/. About JPI: Jade Pharmaceutical through
its subsidiaries JJB & YYB has access to the fastest growing
pharmaceutical and consumer market in the world: China. AMDL,
through its subsidiary, Jade currently manufactures large volume
injectable fluids, tablets and other related products, holding
licenses for 133 products. It also manufactures 107 generic, over
the counter and supplemental pharmaceutical products under
certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be
obtained at http://www.amdl.com/. Forward-Looking Statements: This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct
Line: 949.707.5365 VoiceMail: 714.505.4460 DATASOURCE: AMDL
CONTACT: Mr. Paul Knopick for AMDL Investor Relations,
+1-949-707-5365, voicemail +1-714-505-4460 Web site:
http://www.amdl.com/ http://www.jade-amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024